From: Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
Covariate in model
Patients
HR (Pertuz vs. Control)
HR 95% CI
P value
None
All
0.56
0.22–1.46
0.230
Number prior therapies in Met setting
0.57
0.22–1.50
0.257